Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 5/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 5/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.56 |
| ▸ | BTK | Q06187 | 5/20 | 0.47 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LYN | P07948 | 3/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCND2 | P30279 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188755 | 0.86 | RIPK2 (0.76) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL189165 | 0.84 | FGFR1 (0.51) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL189162 | 0.84 | RIPK2 (0.55) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL189950 | 0.83 | RIPK2 (0.49) | RIPK2ACVR1NOD2BTKFGFR1 | |
| SCHEMBL188862 | 0.82 | ACVR1 (0.53) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL188843 | 0.76 | PTK2 (0.50) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL189326 | 0.75 | ALDH1A1 (0.65) | RIPK2ACVR1NOD2BTKPIK3CA | |
| SCHEMBL14040742 | 0.74 | RIPK2 (0.79) | RIPK2ACVR1NOD2BTKSRC | |
| SCHEMBL188797 | 0.73 | ALDH1A1 (0.63) | RIPK2ACVR1NOD2PIK3CA | |
| SCHEMBL189082 | 0.73 | ALDH1A1 (0.57) | RIPK2ACVR1NOD2BTKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |